DIABETIC
KETOACIDOSIS ASSOCIATED WITH ARIPIPRAZOLE
Zaineb H. Makhzoumi, Leon P. McLean, et al.
Pharmacotherapy 2008; 28:1198-1202
RIASSUNTO
Viene descritto il caso di un uomo di 44 anni, senza storia personale
o familiare di diabete mellito, in terapia con l'antipsicotico atipico
aripiprazolo per disturbi schizofrenici, che ha sviluppato chetoacidosi
diabetica (DKA), corretta con terapia insulinica e idratazione intensiva.
E' necessaria una attenta sorveglianza dei pazienti in terapia con questi
farmaci per prevenire complicazioni anche fatali di iperglicemia.
CASE
REPORT
Metabolic adverse effects such as hyperglycemia, alterations in insulin
sensitivity, and weight gain are known to be potential complications of
atypical antipsychotic therapy. In certain cases, hyperglycemia may be
so profound that diabetic ketoacidosis (DKA) or hyperosmolar coma may
result. Aripiprazole, approved by the United States Food and Drug Administration
in 2002, appears to have fewer metabolic adverse effects than other atypical
antipsychotics.
We describe a 44-year-old man with no personal or family history of diabetes
mellitus who was prescribed aripiprazole for schizoaffective disorder.
Two weeks after starting this therapy, the patient developed DKA, which
was corrected with insulin therapy and aggressive hydration. According
to the Naranjo adverse drug reaction probability scale, aripiprazole was
the probable trigger of his DKA. An exhaustive search for other causes
of DKA was unrevealing. Administration of aripiprazole or any other atypical
antipsychotic should be terminated when impaired glucose tolerance is
suspected. Vigilance regarding the potential adverse effects of this class
of drugs, including new agents such as aripiprazole, is crucial to preventing
potentially life-threatening complications of hyperglycemia.
|